USANA Health Sciences
USANA Health Sciences' revenue rose 8.3% to $925 million in fiscal 2025. Its operating margin was 4.0%, down from 7.8% a year earlier. Free cash flow was $9 million, down 83.3%. It paid out $28 million in dividends and buybacks, 323% of free cash flow. The diluted share count fell 3.1%.
Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on equity is net income as a share of shareholders' equity. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.
Charts show fiscal years, from the 10-K filings.
What USANA Health Sciences does
USANA develops and makes nutritional supplements, functional foods and personal care products and sells them around the world. It was founded in 1992 and operates in 25 geographic markets. In 2025 it had $925 million in net sales and about 387,000 active customers in its core nutritional business.
It has historically sold through direct selling, in which independent Brand Partners sell its products and earn pay under a Compensation Plan. Mainland China is its largest market, at about 41.3% of net sales. It also sells in other ways: directly to consumers, through marketplaces such as Amazon, and through retailers.
In December 2024 it bought a majority interest in Hiya Health Products, which sells children's health and wellness products directly to consumers. In 2022 it bought Rise, a nutrition brand it has expanded.
Its biggest risks, as it describes them
- Direct selling is closely watched and regulated, and changes in law or its enforcement could hurt its business.
- Brand Partners breaking marketing or advertising laws, or promoting its Compensation Plan improperly.
- Changes it must make to its Compensation Plan in some markets, or Brand Partners reacting badly to them.
- Depending on Greater China for much of its business and expected growth, and the strict rules there.
- A decline in sales or customers in China, or the government not approving its BabyCare business model.
Income statement
From fiscal 2016 to 2025, earnings per share fell 19.3% a year and net income 21.9% a year, while buybacks cut the share count by 26%.
Returns on capital
Balance sheet
Five years at a glance
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | 240 | 288 | 330 | 182 | 158 |
| Debt incl. finance leases | — | — | — | — | — |
| Net debt (negative means net cash) | — | — | — | — | — |
| Net debt to EBITDA | — | — | — | — | — |
| Debt to equity | — | — | — | — | — |
| Interest coverage | 2,985.8x | 560.5x | 355.2x | 236.0x | 44.5x |
| Current ratio | 2.3x | 2.7x | 3.5x | 2.0x | 2.2x |
| Quick ratio | 1.7x | 2.2x | 3.0x | 1.5x | 1.4x |
Cash flow
Projections
Project USANA Health Sciences' revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.
What USANA Health Sciences says to expect
- Fiscal 2026: net sales and adjusted EBITDA
We are updating our fiscal 2026 outlook to consolidated net sales approaching $900 million and Adjusted EBITDA of $77 million.
Insider trades
Over the 12 months between November 14, 2025 and November 13, 2026, no insider bought USANA Health Sciences shares on the open market, and 8 insiders sold $894,829.
| Date | Insider | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Jun 16, 2026 | Brent NeidigChief Commercial Officer | Sold | 5,002 | $19.45 | $97,289 | Form 4 |
| Jun 15, 2026 | Brent NeidigChief Commercial Officer | Sold | 909 | $20.01 | $18,189 | Form 4 |
| Jun 12, 2026 | Brent NeidigChief Commercial Officer | Sold | 1,602 | $20.15 | $32,280 | Form 4 |
| Jun 8, 2026 | Paul A. JonesChief People Officer | Sold | 5,561 | $18.50 | $102,878 | Form 4 |
| Jun 1, 2026 | John Turman FlemingDirector | Sold | 2,450 | $17.93 | $43,928 | Form 4 |
| May 28, 2026 | Paul A. JonesChief People Officer | Sold | 6,813 | $18.95 | $129,106 | Form 4 |
| May 27, 2026 | Iiekking G DougChief Financial Officer | Sold | 5,360 | $18.75 | $100,500 | Form 4 |
| May 22, 2026 | Gilbert A FullerDirector | Sold | 1,057 | $18.66 | $19,724 | Form 4 |
| May 7, 2026 | Joshua FoukasChief Legal Officer | Sold | 3,791 | $19.82 | $75,138 | Form 4 |
| Mar 20, 2026 | Gilbert A FullerDirector | Sold | 1,058 | $17.00 | $17,986 | Form 4 |
| Mar 3, 2026 | Peter BenedictChief Information Officer | Sold | 4,553 | $19.38 | $88,237 | Form 4 |
| Feb 20, 2026 | Joshua FoukasChief Legal Officer | Sold | 4,461 | $21.35 | $95,242 | Form 4 |
Indicators
Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.
| Indicator | FY23 | FY24 | FY25 |
|---|---|---|---|
| Piotroski F-score | — | — | — |
| Rule of 40 | −1.7% | −1.3% | 9.2% |
| Altman Z'' | 10.23 | 7.36 | 7.37 |
| Accruals ratio | −1.1% | −2.8% | −1.6% |
The nine F-score tests
| Test | FY23 | FY24 | FY25 |
|---|---|---|---|
| Net income is positive | Pass | Pass | Pass |
| Cash from operations is positive | Pass | Pass | Pass |
| Return on assets rose | Fail | Fail | Fail |
| Cash from operations exceeds net income | Pass | Pass | Pass |
| Debt fell relative to assets | — | — | — |
| Current ratio rose | Pass | Fail | Pass |
| Share count didn't rise | Fail | Pass | Pass |
| Gross margin rose | Pass | Pass | Fail |
| Revenue rose relative to assets | Fail | Fail | Fail |
| F-score | — | — | — |
Compare
Put USANA Health Sciences side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.
Similar companies
| Company | Year | Revenue growth | Operating margin | Free cash flow margin | Return on capital | Net debt to EBITDA | F-score | Compare |
|---|---|---|---|---|---|---|---|---|
| USANA Health Sciences | FY25 | 8.3% | 4.0% | 0.9% | — | — | — | |
| Nu Skin | FY25 | −14.3% | 4.4% | 3.1% | 6.5% | −0.1x | 7 | Compare |
| e.l.f. Beauty | FY26 | 24.6% | 4.5% | 11.6% | 3.8% | 3.6x | 4 | Compare |
| Nature's Sunshine Products | FY25 | 5.7% | 5.2% | 6.0% | 23.6% | −2.4x | 7 | Compare |
| The Honest Company | FY25 | −1.9% | −5.0% | 3.7% | — | — | — | Compare |
10 years of figures
| Fiscal year | FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Revenue | 1,006 | 1,047 | 1,189 | 1,061 | 1,135 | 1,186 | 999 | 921 | 854 | 925 |
| Revenue growth | 9.5% | 4.1% | 13.6% | −10.8% | 7.0% | 4.6% | −15.8% | −7.8% | −7.2% | 8.3% |
| Gross profit | 826 | 868 | 988 | 873 | 926 | 969 | 805 | 744 | 693 | 724 |
| Research and development | 9 | 9 | 10 | 10 | 11 | 11 | 12 | 11 | 12 | 11 |
| Operating income | 139 | 132 | 188 | 146 | 176 | 170 | 108 | 93 | 66 | 37 |
| Net income | 100 | 62 | 126 | 100 | 125 | 116 | 69 | 64 | 42 | 11 |
| Diluted EPS (US$) | 3.99 | 2.53 | 5.12 | 4.41 | 5.86 | 5.73 | 3.59 | 3.30 | 2.19 | 0.58 |
| Diluted shares (millions) | 25 | 25 | 25 | 23 | 21 | 20 | 19 | 19 | 19 | 19 |
| Cash flow | ||||||||||
| Cash from operations | 137 | 124 | 152 | 127 | 160 | 121 | 104 | 71 | 61 | 22 |
| Capital expenditure | 33 | 13 | 11 | 17 | 15 | 13 | 10 | 14 | 10 | 14 |
| Free cash flow | 104 | 111 | 141 | 110 | 145 | 108 | 94 | 56 | 51 | 9 |
| Dividends paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share buybacks | 65 | 50 | 105 | 150 | 57 | 178 | 25 | 12 | 9 | 28 |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 6 | 0 | 203 | 0 |
| Stock-based compensation | 16 | 16 | 15 | 16 | 14 | 14 | 13 | 15 | 15 | 14 |
| Balance sheet at fiscal year end | ||||||||||
| Cash and short-term investments | 176 | 247 | 214 | 235 | 312 | 240 | 288 | 330 | 182 | 158 |
| Debt incl. finance leases | — | — | — | — | — | — | — | — | — | — |
| Total assets | 471 | 519 | 554 | 517 | 641 | 578 | 596 | 633 | 748 | 743 |
| Total liabilities | 145 | 156 | 163 | 165 | 199 | 183 | 162 | 136 | 162 | 157 |
| Shareholders' equity | 325 | 363 | 391 | 352 | 442 | 395 | 434 | 497 | 532 | 533 |
| Margins and ratios | ||||||||||
| Gross margin | 82.1% | 82.9% | 83.1% | 82.3% | 81.6% | 81.6% | 80.6% | 80.8% | 81.1% | 78.3% |
| Operating margin | 13.8% | 12.7% | 15.8% | 13.8% | 15.6% | 14.3% | 10.8% | 10.1% | 7.8% | 4.0% |
| Net margin | 9.9% | 6.0% | 10.6% | 9.5% | 11.0% | 9.8% | 6.9% | 6.9% | 4.9% | 1.2% |
| Free cash flow margin | 10.4% | 10.6% | 11.8% | 10.4% | 12.8% | 9.1% | 9.4% | 6.1% | 6.0% | 0.9% |
| Rule of 40 (growth + FCF margin) | 19.9% | 14.7% | 25.4% | −0.4% | 19.8% | 13.7% | −6.5% | −1.7% | −1.3% | 9.2% |
| Return on capital | — | — | — | — | — | — | — | — | — | — |
| Return on equity | 33.0% | 18.2% | 33.5% | 27.1% | 31.4% | 27.9% | 16.7% | 13.7% | 8.2% | 2.0% |
| Return on assets | 22.4% | 12.6% | 23.5% | 18.8% | 21.5% | 19.1% | 11.8% | 10.4% | 6.1% | 1.4% |
| Net debt to EBITDA | — | — | — | — | — | — | — | — | — | — |